Infantile Spasms and the Vigabatrin Market: A Critical Paediatric Need

Infantile spasms — also known as West syndrome — is a severe, rare form of epilepsy that affects infants, often in the first year of life. Without prompt and effective treatment, it can lead to lasting developmental impairment. Vigabatrin is one of the few therapies proven effective, and it is often the treatment of choice. This critical paediatric need is the primary driver of the vigabatrin market.

Vigabatrin is particularly effective in infantile spasms associated with tuberous sclerosis complex, where it is often first-line. According to vigabatrin market analysis, the infantile spasms indication represents a significant share of the market, driven by the severity of the condition and the limited number of effective treatments. Growth is supported by improved diagnosis and specialist care.

Innovation includes paediatric-friendly powder formulations and improved monitoring protocols for visual safety.

Challenges include the rarity of the condition, visual toxicity risk, and access barriers.

Yet the clinical need is clear, and the market is expected to remain stable as awareness and diagnosis improve.

People Also Ask

Q: Why is vigabatrin used for infantile spasms?
A: It is one of the few treatments proven effective for infantile spasms, particularly in tuberous sclerosis complex.

Q: How common are infantile spasms?
A: They are rare, affecting a small number of infants, but they are severe and require prompt treatment.

Tags: #InfantileSpasms #WestSyndrome #Vigabatrin #PaediatricNeurology #Epilepsy #MarketDrivers

Больше